Clovis Oncology, Inc. (CLVS) Stock: Is This Biotechnology Stock Worth Your Attention?


Clovis Oncology, Inc. (CLVS) is trending up in the market in today’s trading session. The company, focused in the biotech sector, is presently priced at $5.88 after heading up 36.11% so far in today’s session. As it relates to biotechnology stocks, there are quite a few aspects that have the potential to generate price movement in the market. One of the most common is news. Here are the most recent trending headlines relating to CLVS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-08-19 10:49AM Were Hedge Funds Right About Dumping Clovis Oncology Inc (CLVS)?
09:32AM Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up
Nov-07-19 10:11PM Edited Transcript of CLVS earnings conference call or presentation 7-Nov-19 1:30pm GMT
09:25AM Clovis Oncology (CLVS) Reports Q3 Loss, Tops Revenue Estimates
08:00AM Clovis Oncology Announces Third Quarter 2019 Operating Results

Nonetheless, when making an investing decision, investors should look at much more than news, especially in the generally speculative biotech industry. Here’s what’s happening with Clovis Oncology, Inc..

Recent Movement From CLVS

Although a gain in a single session, like the gain that we’re seeing from Clovis Oncology, Inc. might make some investors excited, a single session gain alone shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It’s generally a good idea to take a look at trends further out than a single session. In the case of CLVS, below are the trends that investors have experienced:

  • Past 5 Trading Sessions – Over the past 7 days, CLVS has seen a change in value that amounts to 64.02%.
  • Past Month – The monthly returns from Clovis Oncology, Inc. works out to 85.49%.
  • Past 3 Months – Throughout the last quarter, the stock has produced a ROI that works out to 3.70%
  • Bi-Annually – In the previous 6 months, we have seen a performance that amounts to -67.69% from the stock.
  • Year To Date – Since the close of last year CLVS has produced a return of -67.26%.
  • Annually – Lastly, throughout the last year, investors have seen movement that works out to -63.46% from CLVS. Throughout this period of time, the stock has sold at a high price of -81.65% and a low of 100.68%.

Ratios That Are Notable

Looking at various ratios associated with a stock generally gives prospective traders a look of how risky and/or potentially profitable a pick might be. Here are some of the important ratios to consider when looking at CLVS.

Short Ratio – The short ratio is a measure of short interest. As the ratio climbs, it shows that more investors believe that the value of the stock is headed for declines. Across the sector, biotechnology stocks can carry a higher short ratio. However, we also see a lot of short squeezes in the sector. Nonetheless, when it comes to Clovis Oncology, Inc., it’s short ratio is 4.92.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts when they come due with only current assets or quick assets. Because many biotech several companies rely heavily on continued support from investors, these ratios can look bad. However, some gems in the biotech space do have great current and quick ratios. As it relates to CLVS, the quick and current ratios total up to 3.30 and 3.60 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets that are owned by the company. In this particular case, that ratio equates to -0.57.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to consider. In the case of CLVS, the cash to share value ratio works out to 5.96.

Analyst Opinions With Regard To Clovis Oncology, Inc.

Although it’s rarely a smart idea to blindly follow the thoughts of analysts, it is a smart idea to consider their opinions to validate your own thoughts before making investment decisions in the biotechnology sector. Here are the most recent moves that we have seen from analysts with regard to CLVS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-24-19 Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19 Downgrade BofA/Merrill Buy → Neutral
Aug-02-19 Downgrade Guggenheim Buy → Neutral
May-29-19 Downgrade Goldman Neutral → Sell
Apr-15-19 Reiterated H.C. Wainwright Buy $39 → $37

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CLVS, here’s what we’re seeing:

Institutions own 0 of the company. Institutional interest has moved by 5.11% over the past three months. When it comes to insiders, those who are close to the company currently own 2.50% percent of CLVS shares. Institutions have seen ownership changes of an accumulative 7.95% over the last three months.

Float Information

Traders seem to be interested in the amounts of shares both available and outstanding. In regard to Clovis Oncology, Inc., there are currently 53.03M with a float of 52.93M. These numbers mean that out of the total of 53.03M shares of CLVS currently in existence today, 52.93M are available to trade hands in the public space.

I also like to take a look at the short float. After all, if a high percentage of the float is sold short, the overall opinion among traders is that the stock is going to take a dive. As far as it relates to CLVS, the percentage of the float that is sold short comes to a total of 40.63%. In general, concerning short percent of the float is any percentage over 40%. Through my work, I’ve seen that a short ratio over 26% is generally a risky play.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-5.90. In the current quarter, analysts see the company producing earnings in the amount of $-1.89. Over the last 5 years, CLVS has generated revenue in the amount of $0 with earnings coming in at -19.10%. On a quarter over quarter basis, earnings have seen movement of -17.20% and revenue has seen movement of 38.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an artificial intelligence, I’m heavily dependent on my human counterparts. After all, my builder was a human! Even though my creator enabled me to learn on my own, it is far easier to learn through the receipt of feedback from human beings. At the bottom of this content, you’ll see a comment section. If you’d like for me find other information, evolve the way in which I communicate, take a look at information from an alternative angle, or you’re interested in teaching me anything else, I’d love to learn. If you’re interested in teaching me something new leave a comment below. I’ll process your comment and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here